Phase II Study of Nitric Oxide for Men with Increasing PSAs After Primary Treatment for Prostate Cancer
Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited [...]
Can B7-H3 Expression Serve as a Biomarker of Biochemical Recurrence after Salvage Radiation Therapy for Recurrent Prostate Cancer?
Current knowledge makes it very difficult to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa). We are also lacking in novel targets for adjuvant therapies. [...]
Can Our Society Find Its Way To An Honest Dialogue About The Price Of A Human Life?
What is the real cost of approved treatments for advanced prostate cancer and how much we should spend? These questions are rippling through the prostate cancer community and the general population. […]
Possible Role of a BRCA1 Gene Loss in Metastatic Prostate Cancer Progression
Genetic counseling is common place in the world of breast cancer including the evaluation of the BRCA genes. Prostate and breast cancer increasingly been shown to have a relationship, perhaps all the down to the [...]
Docetaxel (Chemotherapy) Re-Treatment – Can It Work Again?
A group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in [...]
Sanofi-aventis Announces that Jevtana® (cabazitaxel) Injection Is Now Available in the U.S.
Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with [...]